| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
N-Formylglycine targets succinate semialdehyde dehydrogenase as an inhibitor. It is formed by the enzymatic conversion of specific cysteine residues to formylglycine by formylglycine-generating enzymes (FGEs) in the endoplasmic reticulum. As a leukocyte chemoattractant, it may modulate immune cell migration.
|
|---|---|
| ln Vitro |
In vitro, N-formylglycine is used to study enzyme function and bioconjugation techniques. It inhibits succinate semialdehyde dehydrogenase. It acts as a leukocyte chemoattractant, inducing the migration of white blood cells. The compound is also used in studies of post-translational modifications, as formylglycine is a catalytically active residue in certain enzymes.
|
| ln Vivo |
In vivo, N-formylglycine is an endogenous metabolite. As a leukocyte chemoattractant, it may play a role in immune responses and inflammation. The compound is involved in the biosynthesis of certain enzymes through post-translational modification. Its role as a succinate semialdehyde dehydrogenase inhibitor suggests potential effects on GABA metabolism and neurotransmission.
|
| Enzyme Assay |
In vitro enzyme assays for succinate semialdehyde dehydrogenase involve incubating the enzyme with N-formylglycine (1-100 µM) and succinate semialdehyde as substrate in buffer at pH 7.4. NADPH production is monitored spectrophotometrically at 340 nm. Inhibition constants are determined from dose-response curves. For FGE activity assays, the conversion of cysteine to formylglycine is monitored by mass spectrometry or using fluorogenic substrates.
|
| Cell Assay |
For in vitro cell assays, leukocytes are treated with N-formylglycine at concentrations of 0.1-100 µM. Cell migration is assessed using Boyden chamber or transwell assays. Chemotaxis is quantified by counting migrated cells. Cell viability is assessed by MTT assay. For enzyme studies, cell lysates are incubated with the compound, and succinate semialdehyde dehydrogenase activity is measured. Metabolic effects are analyzed by targeted metabolomics.
|
| Animal Protocol |
For in vivo animal studies, N-formylglycine is administered to rodents via oral gavage or intraperitoneal injection at doses of 1-50 mg/kg. Blood and tissue samples are collected for pharmacokinetic analysis. Leukocyte migration is assessed in models of inflammation. Succinate semialdehyde dehydrogenase activity is measured in tissue homogenates. GABA levels are quantified by HPLC or LC-MS/MS to assess effects on GABA metabolism.
|
| ADME/Pharmacokinetics |
N-Formylglycine has a molecular weight of 103.08 and formula C₃H₅NO₃. It is soluble in water and organic solvents. The compound is stable under standard storage conditions. As an N-acylglycine, it is metabolized through glycine pathways. It is a leukocyte chemoattractant and an inhibitor of succinate semialdehyde dehydrogenase.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available in the search results. As an endogenous metabolite, it is expected to have low toxicity at physiological concentrations. The compound's role as a leukocyte chemoattractant suggests it may modulate immune responses at higher concentrations. Standard safety precautions should be followed.
|
| Additional Infomation |
N-Formylglycine is an N-acylglycine formed by the condensation reaction of the amino group of glycine with formic acid. It is both an N-formyl amino acid and an N-acylglycine.
N-Formylglycine (CAS# 2491-15-8) is an endogenous metabolite and research reagent used primarily in studies of enzyme inhibition, leukocyte chemotaxis, and post-translational modifications. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is used in studies of GABA metabolism, immune function, and bioconjugation techniques. It is also used in the study of formylglycine-generating enzymes. |
| Molecular Formula |
C3H5NO3
|
|---|---|
| Molecular Weight |
103.08
|
| Exact Mass |
103.027
|
| CAS # |
2491-15-8
|
| PubChem CID |
75606
|
| Appearance |
White to off-white solid powder
|
| Density |
1.307 g/cm3
|
| Boiling Point |
450.2ºC at 760 mmHg
|
| Melting Point |
149-151 °C
|
| Flash Point |
226.1ºC
|
| Vapour Pressure |
2.33E-09mmHg at 25°C
|
| Index of Refraction |
1.452
|
| LogP |
-0.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
7
|
| Complexity |
80.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C(=O)O)NC=O
|
| InChi Key |
UGJBHEZMOKVTIM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H5NO3/c5-2-4-1-3(6)7/h2H,1H2,(H,4,5)(H,6,7)
|
| Chemical Name |
2-formamidoacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (2425.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (20.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (20.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (20.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.7012 mL | 48.5060 mL | 97.0120 mL | |
| 5 mM | 1.9402 mL | 9.7012 mL | 19.4024 mL | |
| 10 mM | 0.9701 mL | 4.8506 mL | 9.7012 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
